Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells

Sorafenib is a multikinase inhibitor used as a first-line treatment for advanced hepatocellular carcinoma (HCC), but it has shown modest to low response rates. The characteristic tumour hypoxia of advanced HCC maybe a major factor underlying hypoxia-mediated treatment failure. Thus, it is urgent to...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Tian-yi, Zhuang, Lin-han, Hu, Yan, Zhou, Yu-lu, Lin, Wen-kai, Wang, Dan-dan, Wan, Zi-qian, Chang, Lin-lin, Chen, Ying, Ying, Mei-dan, Chen, Zi-bo, Ye, Song, Lou, Jian-shu, He, Qiao-jun, Zhu, Hong, Yang, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967870/
https://www.ncbi.nlm.nih.gov/pubmed/27476430
http://dx.doi.org/10.1038/srep30483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4967870/
https://www.ncbi.nlm.nih.gov/pubmed/27476430
http://dx.doi.org/10.1038/srep30483

Ejemplares similares